Literature DB >> 10511412

Teicoplanin pharmacokinetics in critically ill paediatric patients.

A Sánchez1, J López-Herce, E Cueto, A Carrillo, R Moral.   

Abstract

Twenty-one critically ill children aged between 7 days and 12 years were treated with teicoplanin (three loading dosages of 10 mg/kg at 12 h intervals, followed by a maintenance dosage of 10 mg/kg/day). Serum teicoplanin concentrations were monitored by HPLC. Mean concentrations in plasma 30 min after drug administration were 20 +/- 16.1 mg/L. The volume of distribution was 0.30 L/kg and the terminal half-life was 17.41 h. Only 11% of trough values were >10 mg/L (established as desirable values). In critically ill children a dosage of 10 mg/kg/day does not assure serum trough values >10 mg/L.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511412     DOI: 10.1093/jac/44.3.407

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Authors:  Wei Zhao; Daolun Zhang; Thomas Storme; André Baruchel; Xavier Declèves; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2015-09-05       Impact factor: 4.335

4.  Pharmacokinetics of teicoplanin in an ICU population of children and infants.

Authors:  John C Lukas; Georgios Karikas; Maria Gazouli; Panagiotis Kalabalikis; Tasos Hatzis; Panos Macheras
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

Review 5.  Staphylococcal skin infections in children: rational drug therapy recommendations.

Authors:  Shamez Ladhani; Mehdi Garbash
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

6.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

7.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Authors:  Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

8.  Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.

Authors:  Joon Sik Choi; Jong Min Kim; Dongsub Kim; Si Ho Kim; Heeyeon Cho; Hyung Doo Park; Soo Youn Lee; Cheol In Kang; Yae Jean Kim
Journal:  J Korean Med Sci       Date:  2020-11-30       Impact factor: 2.153

9.  Population pharmacokinetics of teicoplanin in children.

Authors:  V Ramos-Martín; S Paulus; S Siner; E Scott; K Padmore; P Newland; R J Drew; T W Felton; F Docobo-Pérez; B Pizer; F Pea; M Peak; M A Turner; M W Beresford; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

10.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.